



FOR IMMEDIATE RELEASE

20 December 2006

**OXFORD GENE TECHNOLOGY GRANTS DNA SEQUENCE VARIATION
LICENSE TO ILLUMINA, INC.**

Oxford, December 20, 2006 - Oxford Gene Technology (OGT) and Illumina are pleased to announce the completion of a licence agreement granting Illumina access to OGT patents for the detection of DNA sequence variations. The granted licence, which will remain valid for the lifetime of the patents, provides Illumina with certain rights with respect to SNP genotyping.

"OGT continues to develop its licensing programme in the United States and is pleased to licence Illumina to our sequence variation patents which is as part of OGT's broad patent portfolio. OGT's technology combined with Illumina's BeadArray™ technology gives customers access to an extremely powerful SNP detection platform," said Sue Sutton, Vice President Licensing North America at OGT.

"We are pleased to enter into this licensing arrangement with OGT, a company that has been recognised as being at the forefront of microarray technology," said Jay Flatley, President and CEO at Illumina. "Our license with OGT is relevant to a portion of our products and will not materially impact our expected financial results."

- ENDS -

For further information, please contact:

At Oxford Gene Technology:

Nicola Booton-Mander, Marketing Manager

Oxford Gene Technology
Begbroke Science Park,
Sandy Lane, Yarnton
Oxford OX5 1PF
T: +44 1865 856352
F: +44 1865 842116
E: licensing@ogt.co.uk
W: www.ogt.co.uk

Media Inquiries:

OGT:

Annabel Entress, 0207 886 8150 / a.entress@northbankcommunications.com

Sarah Jeffery, 0207 886 8150 / s.jeffery@northbankcommunications.com

Illumina:

Maurissa Bornstein, 858 332 4055 / mbornstein@illumina.com

Notes to editors

About Oxford Gene Technology

- Founded in 1995 by the pioneer of Southern Blotting, Professor Sir Edwin Southern, OGT operates out of Begbroke Business Park near Oxford, with excellent access to a growing network of life science companies
- OGT offers a comprehensive custom microarray consultancy service, from experimental design through all stages to data analysis and interpretation. It has a strong proven track record in providing custom microarray service in a range of applications, and recently announced the launch of its first microarray product, an *Escherichia coli* K12 ChIP on chip, the first ChIP microarray product to be launched as part of OGT's Prokaryotic Chip² family

The key focus areas of OGT include:

1. **Array-based application products and services** for life science research and molecular diagnostics. OGT's flexible and cost-effective, customised DNA microarray service covers a range of applications, offering specialist support and assisting customers with every aspect of their research, from initial consultation and experimental design to probe selection, array design and fabrication through to data analysis and interpretation
2. **Development of innovative platform products** for clinical research and diagnostics

3. **Licensing.** OGT operates an open licensing policy which has successfully provided access for a number of companies to OGT's fundamental intellectual property, particularly in the area of microarrays

4. **Scientific collaborations** to generate diagnostic biomarker intellectual property

For further information on OGT visit <http://www.ogt.co.uk/>.

About Illumina

Illumina (www.illumina.com) develops and markets next-generation tools for the large-scale analysis of genetic variation and function. The Company's proprietary BeadArray technology -- now used in leading genomics centers around the world -- provides the throughput, cost effectiveness and flexibility necessary to enable researchers in the life sciences and pharmaceutical industries to perform the billions of tests necessary to extract medically valuable information from advances in genomics and proteomics. This information will help pave the way to personalized medicine by correlating genetic variation and gene function with particular disease states, enhancing drug discovery, allowing diseases to be detected earlier and more specifically, and permitting better choices of drugs for individual patients.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: this release may contain forward-looking statements that involve risks and uncertainties. Among the important factors that could cause actual results to differ materially from those in any forward-looking statements are the costs and outcome of Illumina's litigation with Affymetrix, the Company's ability to scale and integrate technology acquired from CyVera, the ability to further scale oligo synthesis output and technology to satisfy market demand deriving from the Company's collaboration with Invitrogen, Illumina's ability to further develop and commercialize its BeadArray technologies and to deploy new gene expression and genotyping products and applications for its platform technology, to manufacture robust Sentrix® arrays -- including HumanHap BeadChips -- and Oligator® oligonucleotides, and other factors detailed in the Company's filings with the Securities and Exchange Commission including its recent filings on Forms 10-K and 10-Q or in information disclosed in public conference calls, the date and time of which are released beforehand. Illumina disclaims any intent or obligation to update these forward-looking statements beyond the date of this release.